CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

Salvador-Barbero et al. show that sequential treatment with CDK4/6 inhibitors following DNA-damaging chemotherapy enhances therapeutic benefit in pancreatic cancer models, despite previous reports that concurrent treatment did not.

from Cancer Cell https://ift.tt/2vokbRT